|Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.|
|PMID: 17001400 Owner: NLM Status: MEDLINE|
|AIM: To examine the effects of PEG-IFN-based antiviral therapy in elderly patients with chronic HCV.
METHODS: The charts of patients treated with chronic HCV were reviewed. Patients were defined as elderly if they were 60 years of age or older. The control group consisted of patients younger than 60 years of age who were matched to the treated elderly patients based on sex, treating physician, prescribed treatment and intended prescribed treatment duration. The data recorded included end of treatment response, sustained virological response (SVR), adverse events, dose modification and withdrawal of therapy.
RESULTS: Thirty of 147 (20.4%) elderly patients attending a hepatitis C clinic were treated. The average age of the elderly patients was 65+/-4 years. Forty-three per cent were men and 57% were women. Ten per cent received IFN monotherapy, 70% received a combination of IFN/RBV therapy and 20% received a combination of PEG-IFN/RBV therapy. The overall response rates in the elderly patients compared with the younger patients was 46.7% versus 65.8% (P=0.11) for end of treatment response and 33.3% versus 51.2% (P=0.13) for SVR. The rate of dose modification was 50% in the elderly patients compared with 29% in the control group (P=0.08). Therapy was discontinued in 53% of the elderly compared with 34% of younger patients (P=0.17). The younger patients reported more side effects than elderly patients; although, there were more laboratory abnormalities (anemia, thrombocytopenia and neutropenia) in the elderly patients during therapy than in the younger group (0.93 per patient versus 0.49 per patient, P=0.01).
CONCLUSION: Elderly patients with chronic HCV can be treated successfully. However, they are more at risk to develop cytopenias while on treatment. In such patients, the close monitoring of blood counts is necessary. Larger studies are needed to confirm these findings and to determine whether SVR differs in this population.
|C G Nudo; P Wong; N Hilzenrat; M Deschênes|
|Type: Journal Article|
|Title: Canadian journal of gastroenterology = Journal canadien de gastroenterologie Volume: 20 ISSN: 0835-7900 ISO Abbreviation: Can. J. Gastroenterol. Publication Date: 2006 Sep|
|Created Date: 2006-09-26 Completed Date: 2007-06-12 Revised Date: 2013-06-07|
Medline Journal Info:
|Nlm Unique ID: 8807867 Medline TA: Can J Gastroenterol Country: Canada|
|Languages: eng Pagination: 589-92 Citation Subset: IM|
|Department of Medicine, McGill University Health Centre, Montreal, Canada.|
|APA/MLA Format Download EndNote Download BibTex|
Anemia / chemically induced, epidemiology
Antiviral Agents / administration & dosage*, adverse effects*
Biological Markers / blood
Blood Cell Count
Blood Platelets / drug effects, metabolism
Drug Therapy, Combination
Hemoglobins / drug effects, metabolism
Hepatitis C, Chronic / blood, drug therapy*
Interferon-alpha / administration & dosage, adverse effects
Interferons / administration & dosage, adverse effects
Neutropenia / chemically induced, epidemiology
Neutrophils / drug effects, metabolism
Polyethylene Glycols / administration & dosage, adverse effects
Quebec / epidemiology
Ribavirin / administration & dosage, adverse effects
Severity of Illness Index
Thrombocytopenia / blood, chemically induced*, epidemiology*
|0/Antiviral Agents; 0/Biological Markers; 0/Hemoglobins; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/peginterferon alfa-2a; 0/peginterferon alfa-2b; 36791-04-5/Ribavirin; 76543-88-9/interferon alfa-2a; 9008-11-1/Interferons; 99210-65-8/interferon alfa-2b|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The life, achievements and legacy of a great Canadian investigator: Professor Boris Petrovich Babkin...
Next Document: The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tra...